(Q41622019)

5 October 2017

1 reference

title

Investigational drug therapies of treatment of multiple sclerosis (English)

1 reference

5 October 2017

H S Panitch

1

1 reference

5 October 2017

publication date

1 September 1996

1 reference

Multiple Sclerosis Journal

5 October 2017

published in

1 reference

5 October 2017

volume

2

1 reference

5 October 2017

issue

2

1 reference

5 October 2017

page(s)

66-77

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

5 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The impact of blinding on the results of a randomized, placebo-controlled multiple sclerosis clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Outcomes assessment in multiple sclerosis clinical trials: a critical analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Rationale for immunotherapy in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Exacerbations of multiple sclerosis in patients treated with gamma interferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Interferon-beta impairs induction of HLA-DR antigen expression in cultured adult human astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Circulating adhesion molecules and inflammatory mediators in demyelination: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Cytokine-producing cells in experimental autoimmune encephalomyelitis and multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Impulse conduction in multiple sclerosis: a theoretical basis for modification by temperature and pharmacological agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Membranes, myelin, and the pathophysiology of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Future prospects for the management of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The current status of studies of aminopyridines in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Steroid therapy in multiple sclerosis. Point of view

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Intravenous methylprednisolone for multiple sclerosis in relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Immunotherapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The effect of corticosteroids for acute optic neuritis on the subsequent development of multiple sclerosis. The Optic Neuritis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Management of patients receiving interferon beta-1b for multiple sclerosis: report of a consensus conference

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Interferon-beta specifically inhibits interferon-gamma-induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Interferon beta decreases T cell activation and interferon gamma production in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

A placebo-controlled, randomized, double-masked, variable dosage, clinical trial of azathioprine with and without methylprednisolone in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Overview of azathioprine treatment in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Low-dose (7.5 mg) oral methotrexate reduces the rate of progression in chronic progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

NIH conference. Lupus nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Bladder Complications in Patients Receiving Cyclophosphamide for Systemic Lupus Erythematosus or Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Cyclosporine: a new immunosuppressive agent for organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Differential effect of cyclosporin A on activation signaling in human T cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Randomised double blind controlled trial of cyclosporin in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Cladribine in treatment of chronic progressive multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Interferons in multiple sclerosis. A review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Systemic alpha-interferon therapy of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Systemic lymphoblastoid interferon therapy in chronic progressive multiple sclerosis. I. Clinical and MRI evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The interferons: biological effects, mechanisms of action, and use in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Molecular requirements involved in suppression of eae by synthetic basic copolymers of amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Immunogenic potentials of copolymer I in normal human lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Additive effects of copolymer-1 and interferon beta-1b on the immune response to myelin basic protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Suppressor T cells generated by oral tolerization to myelin basic protein suppress both in vitro and in vivo immune responses by the release of transforming growth factor beta after antigen-specific triggering

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Inhibition of acute, experimental autoimmune encephalomyelitis by the synthetic immunomodulator linomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Treatment of chronic-relapsing experimental autoimmune encephalomyelitis with the synthetic immunomodulator linomide (quinoline-3-carboxamide).

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Phase 1 clinical trial of chimeric monoclonal anti-CD4 antibody in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Effects of 4-aminopyridine on normal and demyelinated mammalian nerve fibres

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Preliminary trial of 3,4-diaminopyridine in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Protein growth factors as potential therapies for central nervous system demyelinative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

Repair of demyelinated lesions by transplantation of purified 0-2A progenitor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F135245859600200202

10.1177/135245859600200202

21 January 2018

Identifiers

DOI

1 reference

5 October 2017

1 reference